All In Biotech

Drug Trial Radar · NCT01839604

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma

A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients With Advanced/Metastatic Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Mar 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

58

Actual

Start

May 2013

Primary completion

Feb 2015

Study completion Feb 2015

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Ionis Pharmaceuticals, Inc.
First posted
Apr 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/Ib open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma.

Conditions

  • Advanced Adult Hepatocellular Carcinoma
  • Hepatocellular Carcinoma Metastatic

Interventions

  • AZD9150Drug

    Intravenous infusion over 3 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities During Cycle 1Time frame: DLT assessment window - Cycle 1 (22 days)

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Hong Kong, Hong Kong

  • Research Site

    Chūōku, Japan

  • Research Site

    Kashiwa-shi, Japan

  • Research Site

    Matsuyama, Japan

  • Research Site

    Seoul, South Korea

  • Research Site

    Tainan, Taiwan

  • Research Site

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.